Predictors of Bilateral Sentinel Lymph Node Mapping Failure in Endometrial Cancer: A Systematic Review and Meta-Analysis.

J Minim Invasive GynecolMay 20, 2026 (epub)
Clinical ResearchOncology (Medical)Obstetrics & Gynecology

Zhaojuan Qin, Yi Du, Qi Wan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined predictors of bilateral sentinel lymph node (SLN) mapping failure in 6,977 patients with early-stage endometrial cancer undergoing minimally invasive surgery. Key findings indicated that obesity (BMI ≥30 kg/m²), high tumor grade (G3), nonendometrioid histology, and lymph node involvement significantly increased the risk of mapping failure, while other factors did not show a significant association.

Key findings

  • Obesity (BMI ≥30 kg/m²) was significantly associated with increased SLN mapping failure.
  • High tumor grade (G3) correlated with a higher risk of bilateral SLN mapping failure.
  • Nonendometrioid histology was linked to increased mapping failure rates.
  • Lymph node involvement was a significant predictor of SLN mapping failure.

Why it matters

Understanding the predictors of SLN mapping failure can help clinicians identify high-risk patients, allowing for tailored surgical planning and improved intraoperative decision-making in endometrial cancer management.

Source

PubMed · PMID 42167542

Published in J Minim Invasive Gynecol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.